Search This Blog

Monday, March 6, 2023

Wedbush Lowers Kala Pharmaceuticals' Price Target to $42 From $47

 

Due to Increased Share Count, Keeps Outperform Rating

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.